Best’s News & Research Service subscription required - September 23, 2025 04:30 PM (EDT)
Widespread adoption of GLP-1 weight-loss drugs could reduce all-cause mortality in the United States by as much as 6.4% by 2045 and the United Kingdom could see a 5% reduction in that timeframe, . . .
-- This content requires a subscription --
Log in Register your purchase
A subscription includes:
Subscribe
Market Research Mortality Prescription Drugs Claims Life Insurance
Reprints & Redistribution
More from Best’s News
More Related Company News